Lamivudine/nevirapine/stavudine

Lamivudine/nevirapine/stavudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Stavudinenucleoside reverse transcriptase inhibitor
Names
Trade namesTriomune, others
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Defined daily dosenot established[1]

Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a medication used to treat HIV/AIDS.[2] It is a fixed dose combination of lamivudine, nevirapine, and stavudine.[2] It is either used by itself or along with other antiretrovirals.[2] It is taken by mouth twice a day.[2]

The medication is generally well tolerated.[3] Side effects are those of the underlying medications.[2] This may include rash, numbness, pancreatitis, and high blood lactate levels.[3] Use is not recommended in those with significant liver problems.[3] It is unclear if use in pregnancy is safe for the baby and recommendations include starting in the second trimester if possible.[3]

The combination was on the World Health Organization's List of Essential Medicines; however, was removed.[4][5] The wholesale cost in the developing world is about 10 USD per month.[6] As of 2015 it is not commercially available in the United States.[7]

Medical uses

It is a common first line treatment in the developing world.[8]

Dosage

The defined daily dose is not established.[1]

References

  1. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 24 September 2020. Retrieved 18 September 2020.
  2. 1 2 3 4 5 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
  3. 1 2 3 4 "Nevirapine/stavudine/lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  4. ↑ "eEML - Electronic Essential Medicines List". list.essentialmeds.org. Archived from the original on 18 June 2022. Retrieved 15 September 2023.
  5. ↑ "Additions and deletions of medicines on the WHO model lists of essential medicines: 1977-2017". WHO. Archived from the original on 8 July 2023. Retrieved 15 September 2023.
  6. ↑ "Lamivudine + Stavudine + Nevirapine". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
  7. ↑ Kasper, Dennis L.; Fauci, Anthony S.; Hauser, Stephen; Longo, Dan; Jameson, J. Larry; Loscalzo, Joseph (2015). Harrison's Principles of Internal Medicine 19/E (Vol.1 & Vol.2). McGraw Hill Professional. p. 1277. ISBN 9780071802161. Archived from the original on 2016-12-20.
  8. ↑ Siegfried, NL; Van Deventer, PJ; Mahomed, FA; Rutherford, GW (19 April 2006). "Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults". The Cochrane Database of Systematic Reviews (2): CD004535. doi:10.1002/14651858.CD004535.pub2. PMID 16625606.
Identifiers:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.